CN1398644A - Stem cell regenerating surface cornea and its application in corneal transplantation - Google Patents
Stem cell regenerating surface cornea and its application in corneal transplantation Download PDFInfo
- Publication number
- CN1398644A CN1398644A CN01123707A CN01123707A CN1398644A CN 1398644 A CN1398644 A CN 1398644A CN 01123707 A CN01123707 A CN 01123707A CN 01123707 A CN01123707 A CN 01123707A CN 1398644 A CN1398644 A CN 1398644A
- Authority
- CN
- China
- Prior art keywords
- cell
- stem cell
- culture
- cornea
- regenerating surface
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 64
- 210000004087 cornea Anatomy 0.000 title claims abstract description 57
- 230000001172 regenerating effect Effects 0.000 title claims abstract description 34
- 238000002054 transplantation Methods 0.000 title claims description 18
- 210000004027 cell Anatomy 0.000 claims abstract description 78
- 210000001691 amnion Anatomy 0.000 claims abstract description 34
- 210000000981 epithelium Anatomy 0.000 claims abstract description 20
- 239000006285 cell suspension Substances 0.000 claims abstract description 15
- 239000001963 growth medium Substances 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 210000004748 cultured cell Anatomy 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 8
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 19
- 102000004142 Trypsin Human genes 0.000 claims description 14
- 108090000631 Trypsin Proteins 0.000 claims description 14
- 239000012588 trypsin Substances 0.000 claims description 14
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 11
- 210000003560 epithelium corneal Anatomy 0.000 claims description 9
- 230000029087 digestion Effects 0.000 claims description 8
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 7
- 210000002249 digestive system Anatomy 0.000 claims description 7
- 206010023365 keratopathy Diseases 0.000 claims description 7
- 238000002372 labelling Methods 0.000 claims description 7
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 6
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 102000004877 Insulin Human genes 0.000 claims description 6
- 108090001061 Insulin Proteins 0.000 claims description 6
- 102000002070 Transferrins Human genes 0.000 claims description 6
- 108010015865 Transferrins Proteins 0.000 claims description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
- 229940125396 insulin Drugs 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 5
- 239000012531 culture fluid Substances 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 claims description 4
- 239000003855 balanced salt solution Substances 0.000 claims description 4
- 239000012533 medium component Substances 0.000 claims description 4
- 229960001881 sodium selenate Drugs 0.000 claims description 4
- 235000018716 sodium selenate Nutrition 0.000 claims description 4
- 239000011655 sodium selenate Substances 0.000 claims description 4
- 102000029816 Collagenase Human genes 0.000 claims description 3
- 108060005980 Collagenase Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 229960002424 collagenase Drugs 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- 239000000020 Nitrocellulose Substances 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 210000002469 basement membrane Anatomy 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 229920001220 nitrocellulos Polymers 0.000 claims description 2
- 210000002826 placenta Anatomy 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 208000006379 syphilis Diseases 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 abstract description 6
- 208000021921 corneal disease Diseases 0.000 abstract 2
- 230000004069 differentiation Effects 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000007547 defect Effects 0.000 description 5
- 206010023683 lagophthalmos Diseases 0.000 description 5
- 230000002980 postoperative effect Effects 0.000 description 5
- 208000006069 Corneal Opacity Diseases 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 231100000269 corneal opacity Toxicity 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000004453 corneal transparency Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007159 enucleation Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- -1 Mus EGF Chemical compound 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000002718 aborted fetus Anatomy 0.000 description 1
- 208000013001 absolute glaucoma Diseases 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Images
Landscapes
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
In the present invention an embryo or adult cornea epithelium is cut, digested with digesting liquid and centrifugated to prepare single cell suspension, and the cell suspension is cultured in culture dish or bottle with proper amount of culture medium and CO2 in 5% at 37 deg.c. The cultured cell is passed after cell converges to 80-90% and the second and sixth generation of cell is passed directly to amnion for culture for another 8-20 days to obtain the stem cell regenerating surface cornea of the present invention. The stem cell regenerating surface cornea may be used as material for treating corneal disease. The present invention provides a new material for treating corneal disease with rich material source, no danger of mouse-originated pollution, no or slight immunological rejection.
Description
Invention field
The present invention relates to a kind of stem cell regenerating surface cornea and the application in corneal transplantation thereof; Particularly relating to embryo or allosome cornea is raw material, stem cell regenerating surface cornea that make in undifferentiated cultivation on the amniotic membrane back of going down to posterity and the application in corneal transplantation thereof.
Background technology
Cornea is the outermost part of eyeball, is the transparent structure of no blood vessel, is positioned at eyeball (so-called iris) foremost.It is important refractive media as camera gun, and extraneous light must at first just can enter ophthalmic by cornea.If hinder, infect or other disease makes become muddy, anterior corneal surface of cornea invade blood vessel because of chemical burn, burn, will have a strong impact on vision, in addition blind.Serious keratopathy need be removed the cornea of the muddy part of patient by the method for operation, replaces the cornea of pathological changes or damage with the healthy transparent cornea of same shape, to reach the recovery vision or to treat the purpose of keratopathy.
Corneal transplantation mainly contains three kinds of modes in the prior art, traditional corneal transplantation, transplants and the allosome edge is transplanted from the body edge, and its main feature is as follows:
1. traditional corneal transplantation is mainly used in the central cornea muddiness that the treatment a variety of causes causes, its advantage is that the post-operative cornea optical zone is transparent, and shortcoming is only to transplant for central φ 6-7mm optical zone, and is invalid for the dry cell gap resisting person, cornea is very fast muddy again, needs secular immunosuppressant therapy in addition.
2. the advantage of transplanting from the body edge is not need immunosuppressant therapy, but strong eye has the danger of the dry cell gap resisting of generation, and can not 360 ° of ring-types transplant, and effect is subjected to certain restriction.
3. the allosome edge is transplanted the operation method of the treatment dry cell gap resisting that is present comparative maturity, but donor material is very limited, and therapy apparatus can be considerably less; Immunologic rejection is arranged, at least one year of postoperative medication, expense is very high.
Along with the development of stem cells technology, in recent years, people have proposed the method that adopts the culturing stem cells cornea to transplant, as CORNEA 2000; 19 (4): the employing bioengineered tissue that discloses Schwab IR etc. among the 421-42 replaces the method for pathological changes cornea, wherein the cell culture of cornea epithelium is the cornea epithelium that adopts from body or relatives, with depositary's amniotic membrane (HAM) is carrier, back differentiation culture cell on HAM goes down to posterity, trophocyte is 3T3, adopt the KGM culture medium, serum-free culture.Though the shortcoming of this method is that cultured cell can be bred in a large number on the 3T3 trophocyte, because of as trophocyte the allos risk of pollution being arranged with the Mus cell; Differentiation culture reduces stem cell population on amniotic membrane in addition, can't guarantee long-term effectiveness.
N ENGL J MED 2000; Among the 43:86-93, people such as Tsai RJF disclose the method for rebuilding impaired cornea by the epithelium of autologous transplanting, wherein the cell culture of cornea epithelium is to adopt the auto corneal cell, and (HAM) is carrier with depositary's amniotic membrane, on HAM piece of tissue former be commissioned to train foster, culture medium is DMEM: F12=1: 1,0.5%DMSO, Mus EGF, bovine insulin, cholera toxin, 5%FBS.The advantage of this method is the autogenous cell cultivation, no rejection does not adopt trophocyte 3T3, but exists the inapplicable and former foster cultural method of being commissioned to train of eyes patient to make stem cell mix existence with noble cells, the shortcoming that stem cell population is limited may also can't guarantee long-term effectiveness.
Summary of the invention
The object of the present invention is to provide a kind of stem cell regenerating surface cornea, it almost is made of pure stem cell, transplants the back and breaks up under concrete conditions in the establishment of a specific crime, and undifferentiated cell is according to regulating from concrete conditions in the establishment of a specific crime, stem cell keeps its of self-replication capacity, can guarantee the long-term effectiveness of cell therapy after the transplant operation; Immunologic rejection is light or do not have immunologic rejection (autogenous cell is cultivated and transplanted), is a kind of new material that can be used for multiple keratopathy treatment.
A further object of the present invention is the purposes of above-mentioned a kind of stem cell regenerating surface cornea in the treatment keratopathy.
To achieve these goals, the technical solution used in the present invention is: get embryo's corneal epithelium or adult's limbal epithelium, it is shredded the back digest with the Digestive system that contains enzyme.After stopping digestion, centrifugal preparation single cell suspension is used for cultivating; Single cell suspension is placed culture dish or culture bottle, add an amount of culture medium culturing, condition of culture is 5%CO
2, 37 ℃.Changed liquid once in the every 2-3 of cultured cell days; Go down to posterity when reaching 80-90% when cell converges, 2-6 directly is passaged on the amniotic membrane undifferentiated for cell cultivates, cultivate again with same condition of culture and promptly obtain stem cell regenerating surface cornea of the present invention after 8-20 days, can be used as the material of transplantation treatment keratopathy.
Behind the described stem cell regenerating surface cornea implant into body, in breaking up under concrete conditions in the establishment of a specific crime, undifferentiated cell is according to regulating from concrete conditions in the establishment of a specific crime, and stem cell keeps its of self-replication capacity, reaches the purpose of treatment keratopathy.
Wherein, adult's limbal epithelium of the present invention is meant the adult that is different from the embryo, can be the child of some months or the adult at any age.
Described Digestive system can be trypsin+EDTA, trypsin, collagenase, DispaseI or DispaseII, and they one or more combination; Preferred trypsin or trypsin+EDTA; Trypsin+EDTA most preferably.
Described termination digestion can be adopted hyclone, DMEM+ hyclone or hanks liquid+FBS, and their one or more combination realizes; Preferred hyclone or the DMEM+ hyclone of adopting; Most preferably adopt the DMEM+ hyclone.
Described culture fluid comprises: DMEM (Dulbecco ' s modified eagle ' smedium): Ham ' s F12 is 1: 1-3: 1,10% hyclone, epidermal growth factor EGF (10-20ng/ml).
Described culture fluid further comprises: basic fibroblast growth factor bFGF (10-30ng/ml), insulin (5-40ug/ml), transferrins (1-10ug/ml), trilute (1-3nM), glutamine 1-8mM, sodium selenate
0-8ug/ml
Described amniotic membrane adopts following method to handle: the Placenta Hominis of selecting that the cesarean puerpera is produced, no HIV, hepatitis B, hepatitis C and syphilis, under aseptic condition, clean blood clot with balanced salt solution, passivity is separated amniotic membrane, the balanced salt solution that reuse contains gentamycin 40,000 U/200ML cleans amniotic membrane three times, is cut into 2.5*2.5CM
2Size, basement membrane of epithelium upwards are attached on the autoclaved nitrocellulose filter, add equivalent DMEM and glycerol, in-80 ℃ of storages.When the preservation amniotic membrane is used for cell culture, first aquation 30 minutes in PBS, reuse trypsin+EDTA (or single EDTA that uses) digestion 3 hours, strike off its epithelium with cell scraper then, reuse PBS washes 3 times, the epithelium basal surface upwards is tiled in the culture dish, the cell seeding that goes down to posterity can be cultivated on it.
See under the inverted microscope that the cell that attaches on the amniotic membrane is the polygon of circle rather than differentiation corneal epithelium; Cell carries out the evaluation of cellular immunization histochemistry with the BrdU labelling on the amniotic membrane after 24 hours, positive cell is at 15-40%, the slow cycle characteristics of the low mark rate prompting stem cell of cell proves that the 2-6 that obtains after going down to posterity is a stem cell for cell, is exactly needed stem cell regenerating surface cornea.
The present invention is a raw material with embryo's corneal epithelium or adult's limbal epithelium, adopts bionic method to prepare a kind of stem cell regenerating surface cornea that is almost single color stem cell.Transplant the back and breaks up under concrete conditions in the establishment of a specific crime, undifferentiated cell keeps the of self-replication capacity of stem cell, can duplicate and breaks up according to regulate it from concrete conditions in the establishment of a specific crime, can guarantee the long-term effectiveness of cell therapy after the transplant operation; Method of the present invention and products material source is abundant, the contact scar danger of no Mus source, immunologic rejection gently or do not have an immunologic rejection, for new way has been opened up in cornea tissue and organ defect, handicapped treatment etc.
Describe the present invention in detail below in conjunction with drawings and Examples, described embodiment is used to describe the present invention, rather than restriction the present invention.
Description of drawings
Fig. 1 is the BrdU labeled cell;
Fig. 2 is the dry cell gap resisting lagophthalmos: the corneal opacity, new vessels, epithelial defect;
Fig. 3 is a stem cell regenerating surface cornea transplantation treatment dry cell gap resisting lagophthalmos.
The specific embodiment
Embodiment 1
On 13 all embryos aborted fetus in age eyes, get whole corneal epitheliums, it is shredded the back digested 15 minutes with 3ML0.1% trypsin+0.02%EDTA, stop digestion with equivalent DMEM+10% hyclone, behind centrifugal 10 minutes of the 1500RPM, add the medium preparation single cell suspension, the 1.5ML single cell suspension is placed the 35MM plastic culture dish, add culture medium at 5%CO
2, 37 ℃ cultivate down.
Medium component: DMEM: F12=1: 1,10% hyclone, epidermal growth factor EGF (10ng/ml), basic fibroblast growth factor bFGF (20ng/ml), insulin (5ug/ml), transferrins (5ug/ml), trilute (2nM), glutamine 4mM, sodium selenate 5ug/ml.
Incubation: cultured cell changed culture medium once in per 2 days, cell converged when reaching 80-90% and goes down to posterity in 20 days, passed for the 2nd generation again in 10 days, passed for the 3rd generation again in 8 days, third generation cell directly is passaged on the amniotic membrane that has dealt with, after cultivating 14 days again with same condition of culture, obtain stem cell regenerating surface cornea and be used for transplantation treatment.Wherein the processing method of amniotic membrane is described in detail in summary of the invention.
See under the inverted microscope to attach the polygon that cell is circle rather than differentiation corneal epithelium on the amniotic membrane, cell growth state is good, and cell is assembled, and is exactly needed stem cell regenerating surface cornea.Cell BrdU labelling row cellular immunization histochemistry evaluation after 24 hours on the amniotic membrane, as shown in Figure 1, the BrdU positive cell accounts for 27.2%, and part cell feminine gender, the low mark rate of cell meets the slow cycle characteristics of stem cell.The slow cycle characteristics of the low mark rate prompting stem cell of cell, prove obtain after going down to posterity the 3rd generation cell be stem cell, be exactly needed stem cell regenerating surface cornea.
Embodiment 2
Carry out because of the left eye absolute glaucoma getting its limbal epithelium immediately after the left eye content enucleation 65 years old male patient, epithelium is shredded the back to be digested 40 minutes with 0.1% trypsin+0.02%EDTA, stop digestion with equivalent DMEM+10% hyclone, centrifugal 10 minutes of 1200RPM, add following culture medium and make single cell suspension, will add culture medium culturing in the 1.5ML single cell suspension immigration 35MM plastic culture dish.Condition of culture is 5%CO
2, 37 ℃.
Medium component: DMEM: F12=3: 1,10% hyclone, epidermal growth factor EGF (20ng/ml), basic fibroblast growth factor bFGF (10ng/ml), insulin (10ug/ml), transferrins (10ug/ml), trilute (1nM), glutamine 8mM.
Incubation: cultured cell changed liquid once in per 3 days, cell converged when reaching 80-90% and goes down to posterity in 22 days, passed for the 2nd generation again in 9 days, passed for the 3rd generation again in 8 days, third generation cell directly is passaged on the amniotic membrane of having done with last processing described in the embodiment 1, with same condition of culture again undifferentiated cultivate and to obtain a kind of stem cell regenerating surface cornea after 14 days, be used for transplantation treatment.
See under the inverted microscope to attach the polygon that cell is circle rather than differentiation corneal epithelium on the amniotic membrane, cell growth state is good, and cell is assembled, and is exactly needed stem cell regenerating surface cornea.Cell BrdU labelling row cellular immunization histochemistry evaluation after 24 hours on the amniotic membrane, the BrdU positive cell accounts for 20%, and part cell feminine gender, the low mark rate of cell meets the slow cycle characteristics of stem cell.The slow cycle characteristics of the low mark rate prompting stem cell of cell, prove obtain after going down to posterity the 3rd generation cell be stem cell.
With the gained corneal transplantation to the corneal opacity shown in Figure 2, new vessels is arranged, on the damaged animal model lagophthalmos of the stem cell of epithelial defect.As shown in Figure 3, the post-operative cornea new vessels disappears, corneal transparency.
Embodiment 3
Carry out because of wound getting its limbal epithelium immediately after the left eye content enucleation 10 years old male patient, this epithelium is shredded the back with 0.1% trypsinization 70 minutes, equivalent 10% hyclone stops digestion, centrifugal 10 minutes of 1200RPM, add following culture medium and make single cell suspension, the 1.5ml single cell suspension is moved in the 35MM plastic culture dish cultivate.Condition of culture is 5%CO
2, 37 ℃.
Medium component: described culture fluid comprises: DMEM:Ham ' s F12 is 2: 1,10% hyclone, epidermal growth factor EGF15ng/ml.
Incubation: cultured cell changed liquid once in per 1 day, cell converged when reaching 80-90% and goes down to posterity in 25 days, passed for the 2nd generation again in 8 days, passed for the 3rd generation again in 7 days, third generation cell directly is passaged to have been done with on the amniotic membrane of handling described in the embodiment 1, same condition of culture undifferentiated was again cultivated after 15 days, obtained a kind of stem cell regenerating surface cornea, was used for transplantation treatment.
See under the inverted microscope to attach the polygon that cell is circle rather than differentiation corneal epithelium on the amniotic membrane, cell growth state is good, and cell is assembled, and is exactly needed stem cell regenerating surface cornea.Cell BrdU labelling row cellular immunization histochemistry evaluation after 24 hours on the amniotic membrane, the BrdU positive cell accounts for 35%, and part cell feminine gender, the low mark rate of cell meets the slow cycle characteristics of stem cell.The slow cycle characteristics of the low mark rate prompting stem cell of cell, prove obtain after going down to posterity the 3rd generation cell be stem cell.
With the gained corneal transplantation to the corneal opacity, new vessels is arranged, on the damaged animal model lagophthalmos of the stem cell of epithelial defect.The post-operative cornea new vessels disappears, corneal transparency.
Embodiment 4
Experimental condition referring to embodiment 3 is produced single cell suspension, and wherein Digestive system adopts collagenase and DispaseI, stops Digestive system and adopts outside hyclone and the hanks liquid+FBS; Culture medium employing DMEM (Dulbecco ' s modified eagle ' s medium): Ham ' s F12 is 2: 1,10% hyclone, epidermal growth factor EGF 12ng/ml; Basic fibroblast growth factor bFGF 30ng/ml, insulin 40ug/ml, transferrins 1ug/ml, trilute 3nM, glutamine 1mM, sodium selenate 8ug/ml.
Incubation: cultured cell changed liquid once in per 5 days, cell converged when reaching 80-90% and goes down to posterity in 18 days, passed for the 2nd generation again in 7 days, passed for the 3rd generation again in 6 days, passed the 4th generation or the like again in 5 days, the 6th generation cell directly be passaged on the amniotic membrane of the same processing, after same condition of culture is cultivated 8 days again, obtain a kind of stem cell regenerating surface cornea, be used for transplantation treatment.
See under the inverted microscope to attach the polygon that cell is circle rather than differentiation corneal epithelium on the amniotic membrane, cell growth state is good, and cell is assembled, and is exactly needed stem cell regenerating surface cornea.Cell BrdU labelling row cellular immunization histochemistry evaluation after 24 hours on the amniotic membrane, the BrdU positive cell accounts for 15%, and part cell feminine gender, the low mark rate of cell meets the slow cycle characteristics of stem cell.The slow cycle characteristics of the low mark rate prompting stem cell of cell, prove obtain after going down to posterity the 3rd generation cell be stem cell.
With the gained corneal transplantation to the corneal opacity, new vessels is arranged, on the damaged animal model lagophthalmos of the stem cell of epithelial defect.The post-operative cornea new vessels disappears, corneal transparency.
Embodiment 5
Referring to the method for embodiment 3, institute's difference directly is passaged on the amniotic membrane of having done with processing described in the embodiment 1 after being to pass the second filial generation, and same condition of culture undifferentiated was again cultivated after 15 days, obtained a kind of stem cell regenerating surface cornea.Cell BrdU labelling row cellular immunization histochemistry evaluation after 24 hours on the amniotic membrane, the BrdU positive cell accounts for 15%, and part cell feminine gender, the low mark rate of cell meets the slow cycle characteristics of stem cell.The slow cycle characteristics of the low mark rate prompting stem cell of cell, prove obtain after going down to posterity the 2nd generation cell be stem cell.
Claims (9)
1. a stem cell regenerating surface cornea is got embryo's corneal epithelium or adult's limbal epithelium, shreds the back and digests with the Digestive system that contains enzyme, and after the termination digestion, centrifugal preparation single cell suspension also is used for cultivating; Single cell suspension is placed culture dish or culture bottle, add culture medium at 5%CO
2, cultivate under 37 ℃ of conditions; Go down to posterity when reaching 80-90% when cell converges, 2-6 directly is passaged on the treated amniotic membrane for cell, and same condition of culture undifferentiated is again cultivated the stem cell regenerating surface cornea of the material that promptly obtains can be used as the transplantation treatment keratopathy after 8-20 days.
2. a kind of stem cell regenerating surface cornea according to claim 1, the described Digestive system that contains enzyme is trypsin+EDTA, trypsin, collagenase, one or more combination of DispaseI or DispaseII; Preferred trypsin or trypsin+EDTA
3. a kind of stem cell regenerating surface cornea according to claim 1, described termination Digestive system adopt one or more combination of hyclone, DMEM+ hyclone or hanks liquid+FBS; Preferred hyclone, or DMEM+ hyclone.
4. a kind of stem cell regenerating surface cornea according to claim 1, wherein said culture fluid comprises 1: 1-1: 3 DMEM:F12,10% FBS, the EGF of 10-20ng/ml.
5. a kind of stem cell regenerating surface cornea according to claim 4, wherein said culture fluid further comprises: 10-30ng/ml basic fibroblast growth factor bFGF, the 5-40ug/ml insulin, the 1-10ug/ml transferrins, the 1-3nM trilute, glutamine 1-8mM, sodium selenate 0-8ug/ml.
6. a kind of stem cell regenerating surface cornea according to claim 1, it is as follows that wherein said amniotic membrane is handled the employing method: choose the Placenta Hominis of selecting that the cesarean puerpera is produced, no HIV, hepatitis B, hepatitis C and syphilis, under aseptic condition, clean blood clot with balanced salt solution, passivity is separated amniotic membrane, the balanced salt solution that reuse contains gentamycin 40,000 U/20ML cleans amniotic membrane three times, be cut into the 2.5*2.5CM2 size, basement membrane of epithelium upwards is attached on the autoclaved nitrocellulose filter, add equivalent DMEM and glycerol ,-80 ℃ of storages; When preserving amniotic membrane and being used for cell culture, aquation 30 minutes in PBS earlier, reuse trypsin+EDTA digested 3 hours, struck off its epithelium with cell scraper then, and reuse PBS washes 3 times, and the epithelium basal surface upwards is tiled in the culture dish.
7. a kind of stem cell regenerating surface cornea according to claim 6, described preparation process is: get limbal epithelium, shredding the back digested 40 minutes with 0.1% trypsin+0.02%EDTA, equivalent DMEM+10% hyclone stops digestion, centrifugal 10 minutes of 1200RPM, the adding culture medium is made single cell suspension, gets in the 1.5ml single cell suspension immigration 35MM plastic culture dish to add culture medium at 5%CO
2, 37 ℃ cultivate down;
Described medium component: DMEM: F12=3: 1,10% hyclone, 20ng/ml epidermal growth factor EGF, 10ng/ml basic fibroblast growth factor bFGF, insulin 10ug/ml, 10ug/ml transferrins, the 1nM trilute, the 8mM glutamine;
Incubation: cultured cell changed liquid once in per 3 days, cell converged the 80-90% epoch that reach in 22 days, passed for the 2nd generation again in 9 days, passed for the 3rd generation again in 8 days, third generation cell directly is passaged on the amniotic membrane of the same processing, after same condition of culture is cultivated 14 days again, obtain a kind of stem cell regenerating surface cornea that is used for transplantation treatment.
8. according to each described a kind of stem cell regenerating surface cornea of claim 1-7, it is characterized in that cell uses the BrdU labelling after 24 hours on the amniotic membrane, positive cell is at 15-40%.
9. the described a kind of stem cell regenerating surface cornea of claim 1, the application on cornea is transplanted.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011237074A CN1218755C (en) | 2001-07-27 | 2001-07-27 | Stem cell regenerating surface cornea and its application in corneal transplantation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011237074A CN1218755C (en) | 2001-07-27 | 2001-07-27 | Stem cell regenerating surface cornea and its application in corneal transplantation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1398644A true CN1398644A (en) | 2003-02-26 |
| CN1218755C CN1218755C (en) | 2005-09-14 |
Family
ID=4665233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011237074A Expired - Fee Related CN1218755C (en) | 2001-07-27 | 2001-07-27 | Stem cell regenerating surface cornea and its application in corneal transplantation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1218755C (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2279887C2 (en) * | 2004-06-10 | 2006-07-20 | Московский научно-исследовательский институт глазных болезней им. Гельмгольца Минздрава РФ | Method for treating cornea defect cases |
| CN1326502C (en) * | 2003-08-07 | 2007-07-18 | 中山大学中山眼科中心 | Artificial tissue engineeing biological cornea |
| CN100336567C (en) * | 2004-10-19 | 2007-09-12 | 北京科宇联合干细胞生物技术有限公司 | Medical cornea paster and its preparation method |
| CN100554411C (en) * | 2004-01-27 | 2009-10-28 | 利莱恩斯生命科学有限公司 | An undifferentiated stem cell tissue system from the limbus |
| WO2010108400A1 (en) * | 2009-03-23 | 2010-09-30 | 中国海洋大学 | Method for reconstructing tissue engineered human corneal endothelium |
| CN101945676A (en) * | 2007-12-19 | 2011-01-12 | 伊西康公司 | Decellularized omentum matrix and uses thereof |
| CN102166374A (en) * | 2010-11-03 | 2011-08-31 | 山东省眼科研究所 | Method for preparing amniotic compound corneal limbus stem cell membrane |
| CN103725643A (en) * | 2013-12-30 | 2014-04-16 | 厦门大学 | Method of constructing corneal endothelium of tissue engineering |
| CN103966166A (en) * | 2014-05-26 | 2014-08-06 | 北京赛贝生物技术有限公司 | Urine cell culture medium and culture method for urine cells |
| CN104789521A (en) * | 2014-01-22 | 2015-07-22 | 广州康睿生物医药科技有限公司 | A separation culture method for lens epithelium stem cells |
| CN105031668A (en) * | 2015-09-09 | 2015-11-11 | 北京大学第一医院 | Device and method for establishing living rabbit keratectasia model |
| CN101437939B (en) * | 2006-04-28 | 2016-08-10 | 蔡曜年 | Method for Expansion of Human Corneal Endothelial Cells |
| CN106916787A (en) * | 2017-02-15 | 2017-07-04 | 中山大学中山眼科中心 | A kind of limbal stem cell culture medium and its cultural method |
| CN107847642A (en) * | 2016-01-08 | 2018-03-27 | 亚果生医股份有限公司 | Acellular cornea and preparation method and application thereof |
| CN108619568A (en) * | 2018-04-28 | 2018-10-09 | 山东省眼科研究所 | A kind of mini plant piece and preparation method thereof for cell transplantation |
| CN115068504A (en) * | 2021-03-12 | 2022-09-20 | 广州康睿生物医药科技股份有限公司 | Cornea repairing material and preparation method and application thereof |
-
2001
- 2001-07-27 CN CNB011237074A patent/CN1218755C/en not_active Expired - Fee Related
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1326502C (en) * | 2003-08-07 | 2007-07-18 | 中山大学中山眼科中心 | Artificial tissue engineeing biological cornea |
| CN100554411C (en) * | 2004-01-27 | 2009-10-28 | 利莱恩斯生命科学有限公司 | An undifferentiated stem cell tissue system from the limbus |
| RU2279887C2 (en) * | 2004-06-10 | 2006-07-20 | Московский научно-исследовательский институт глазных болезней им. Гельмгольца Минздрава РФ | Method for treating cornea defect cases |
| CN100336567C (en) * | 2004-10-19 | 2007-09-12 | 北京科宇联合干细胞生物技术有限公司 | Medical cornea paster and its preparation method |
| CN101437939B (en) * | 2006-04-28 | 2016-08-10 | 蔡曜年 | Method for Expansion of Human Corneal Endothelial Cells |
| CN101945676B (en) * | 2007-12-19 | 2014-07-09 | 伊西康公司 | Decellularized omentum matrix and uses thereof |
| CN101945676A (en) * | 2007-12-19 | 2011-01-12 | 伊西康公司 | Decellularized omentum matrix and uses thereof |
| WO2010108400A1 (en) * | 2009-03-23 | 2010-09-30 | 中国海洋大学 | Method for reconstructing tissue engineered human corneal endothelium |
| CN102166374B (en) * | 2010-11-03 | 2013-12-04 | 山东省眼科研究所 | Method for preparing amniotic compound corneal limbus stem cell membrane |
| CN102166374A (en) * | 2010-11-03 | 2011-08-31 | 山东省眼科研究所 | Method for preparing amniotic compound corneal limbus stem cell membrane |
| CN103725643A (en) * | 2013-12-30 | 2014-04-16 | 厦门大学 | Method of constructing corneal endothelium of tissue engineering |
| CN103725643B (en) * | 2013-12-30 | 2015-12-30 | 厦门大学 | A kind of method building tissue engineering comea endothelium |
| CN104789521A (en) * | 2014-01-22 | 2015-07-22 | 广州康睿生物医药科技有限公司 | A separation culture method for lens epithelium stem cells |
| CN104789521B (en) * | 2014-01-22 | 2017-11-07 | 广州康睿生物医药科技股份有限公司 | A kind of isolated culture method of lens epithelium stem cell |
| CN103966166A (en) * | 2014-05-26 | 2014-08-06 | 北京赛贝生物技术有限公司 | Urine cell culture medium and culture method for urine cells |
| CN103966166B (en) * | 2014-05-26 | 2017-01-18 | 北京赛贝生物技术有限公司 | Urine cell culture medium and culture method for urine cells |
| CN105031668A (en) * | 2015-09-09 | 2015-11-11 | 北京大学第一医院 | Device and method for establishing living rabbit keratectasia model |
| CN105031668B (en) * | 2015-09-09 | 2018-03-16 | 北京大学第一医院 | A kind of device and its construction method for realizing live body rabbit corneal expansion model |
| CN107847642A (en) * | 2016-01-08 | 2018-03-27 | 亚果生医股份有限公司 | Acellular cornea and preparation method and application thereof |
| CN107847642B (en) * | 2016-01-08 | 2021-04-20 | 亚果生医股份有限公司 | Decellularized cornea and preparation method and use thereof |
| CN106916787A (en) * | 2017-02-15 | 2017-07-04 | 中山大学中山眼科中心 | A kind of limbal stem cell culture medium and its cultural method |
| CN108619568A (en) * | 2018-04-28 | 2018-10-09 | 山东省眼科研究所 | A kind of mini plant piece and preparation method thereof for cell transplantation |
| CN108619568B (en) * | 2018-04-28 | 2020-11-20 | 山东省眼科研究所 | Mini-implant for cell transplantation and preparation method thereof |
| CN115068504A (en) * | 2021-03-12 | 2022-09-20 | 广州康睿生物医药科技股份有限公司 | Cornea repairing material and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1218755C (en) | 2005-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1218755C (en) | Stem cell regenerating surface cornea and its application in corneal transplantation | |
| CN101757691B (en) | Preparation method of tissue engineering cornea | |
| CN101433478B (en) | Whole layer biological cornea as well as construction method and use thereof | |
| CN102952777B (en) | Inducing method for directionally differentiating human embryonic stem cells to corneal endothelial cells | |
| JP5255846B2 (en) | Corneal endothelial preparation capable of cell proliferation in vivo | |
| CN102166375B (en) | Reconstruction method of tissue engineering human corneal epithelium | |
| KR101293364B1 (en) | Method for reconstructing tissue engineered human corneal endothelium | |
| CN103656742B (en) | Preparation method of functionalized retinal pigment epithelial cell graft | |
| Wang et al. | Applications of biomaterials in corneal endothelial tissue engineering | |
| CN1473551A (en) | Artificial tissue engineeing biological cornea | |
| AU2001253802B2 (en) | Method for expansion of epithelial stem cells | |
| US20040009590A1 (en) | Method for growth of human conjunctival tissue equivalents for research, clinical ocular surface transplantation and tissue engineering | |
| CN1242058C (en) | Preparation method and application of epidermal stem cell constructed tissue engineering corneal epithelial implant | |
| CN102552979A (en) | Method for preparing cornea lamina material | |
| CN109439628B (en) | Primary culture method of limbal stem cells | |
| CN102166374B (en) | Method for preparing amniotic compound corneal limbus stem cell membrane | |
| CN101597592B (en) | Human corneal endothelial cell culture solution as well as preparation method and application thereof | |
| Huang et al. | An active artificial cornea with the function of inducing new corneal tissue generation in vivo—A new approach to corneal tissue engineering | |
| KR102096724B1 (en) | Acellular cornea, method for manufacturing acellular cornea and use thereof | |
| CN108277204A (en) | A kind of method that bioengineering cultivates eye Full-thickness corneal | |
| CN1289156C (en) | Tissue engineering autologous cornea epithelium and its preparation method | |
| CN116829699B (en) | Application of retinal pigment epithelial cells in replacing corneal endothelium | |
| CN111110921A (en) | A method for in vitro construction of lamellar cornea after tissue engineering | |
| CN109069696B (en) | Acellular pig lamellar dry cornea and use method and application thereof | |
| KR101655333B1 (en) | Surface-modified Silk Fibroin Implant for Biological Film and Preparation Method Thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050914 Termination date: 20100727 |